7Hoskins WJ.Epithelial ovarian carcinoma: principles of primary surgery [J].Gynecol Oncol,1994,55(3Pt 2):s91-96.
8Le T,Krepart GV,Lotocki RJ,et al.Does debulking surgery improve survival in biologically aggressive ovarian carcinoma? [J].Gynecol Oncol,1997,67(2):208-214.
9Chi DS,Liao JB,Leon LF,et al.Identification of prognostic factors in advanced epithelial ovarian carcinoma [J].Gynecol Oncol,2001,82(3):532-537.
10Bristow RE,Tomacruz RS,Armstrong DK,et al.Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta analysis [J].J Clin Oncol,2002,20(5):1248-1259.
7Bast RC Jr, Feeney M, Lazarus H, et al. Reactivity of a monoclonal antibody with human ovarian carcinoma[J]. J Clin Invest, 1981, 68 (5) : 1331-1337.
8Beastall GH, Cook B, Rustin GJ, et al. A review of the role of established tumour markers[J]. Ann Clin Biochem, 1991, 28(Pt 1):5-18.
9Diefanbach CS, Gnjatic S, Sabbatini P, et al. Safety and immunogenicity study of NY-ESO-lb peptide and mon- tanide ISA-51 vaccination of patients with epithelial ova- rian cancer in high-risk first remission[J]. Clin Cancer Res, 2008, 14(9) :2740-2748.
10Lloyd KO, Yin BW, Kudryashov V. Isolation and cha- racterization of ovarian cancer antigen CA 125 using a new monoelonal antibody (VK-8): Identification as a mu- cin-type molecule[J]. Int J Cancer, 1997, 71 (5):842- 850.
